Fluvoxamine possible treatment for mild-to-moderate COVIDIn a preliminary study conducted on 152 patients with mild-to-moderate COVID-19 infections, no patient in a group of 80 people who took a 15-day course of fluvoxamine, an antidepressant, reported clinical deterioration, as opposed to 6 (8.3%) of 72 who took a placebo.The study, published yesterday in JAMA, defined clinical deterioration as severe shortness of breath, hospitalization for shortness of breath or pneumonia, or when oxygen saturation fell below 92% without aid.While both groups had lesser symptoms of adverse events, the fluvoxamine group reported no serious consequences during treatment, whereas the placebo group included four people who had to be rehospitalized. (The one